Masarykuv Onkologicky Ustav

At Masarykuv Onkologicky Ustav researchers are evaluating innovative anticoagulation strategies to reduce cancer‑associated clotting risk, including trials of new agents for venous thromboembolism (VTE) in patients with gastrointestinal and genitourinary malignancies.

• Prevention of VTE recurrence in oncology patients
• Comparative safety of novel oral anticoagulants versus standard therapy
• Impact of anticoagulation on overall survival in high‑risk cancer cohorts

With 91 active studies and 58 investigators, the department demonstrates a strong commitment to cardio‑oncology and patient safety.

Clinical programs focus on targeted therapies for gastrointestinal cancers, such as trials addressing FGFR2b overexpression in gastric tumors and evaluating inhibitors for KRAS G12C mutation in colorectal cancer.

• Advanced gastric and gastro‑esophageal junction adenocarcinoma
• KRAS‑mutated colorectal cancer
• Metastatic pancreatic ductal adenocarcinoma
• FGFR2b‑positive gastric cancer

The site’s multidisciplinary team integrates endoscopy, surgery, and medical oncology to accelerate therapeutic development.

Research includes precision‑medicine approaches for ovarian and endometrial cancers, with studies on BRCA‑mutated ovarian cancer and immunotherapy for PD‑L1‑positive triple‑negative breast cancer.

• BRCA‑mutated high‑grade serous ovarian cancer
• Advanced endometrial carcinoma with molecular profiling
• Triple‑negative breast cancer expressing PD‑L1
• Fallopian tube and primary peritoneal malignancies

By collaborating with gynecologic oncology specialists, the clinic aims to improve outcomes for women across the disease spectrum.

The department conducts pivotal studies on prostate cancer, including trials for metastatic castration‑resistant prostate cancer and investigations of novel hormonal agents in earlier disease stages.

• Biochemically recurrent prostate cancer
• Metastatic castration‑resistant prostate cancer
• Hormone‑sensitive prostate cancer with high‑risk features
• Combination strategies with androgen deprivation therapy

The site leverages advanced imaging and biomarker analysis to personalize treatment pathways for male patients.

A broad portfolio addresses solid tumours at advanced stages, testing new immunotherapies, kinase inhibitors, and antibody‑drug conjugates across multiple cancer types, including advanced solid tumors.

• Advanced breast cancer (HR‑positive, HER2‑negative and HER2‑positive)
• Metastatic melanoma, including NRAS‑mutant disease
• Non‑small cell lung cancer with diverse genomic alterations
• Renal cell carcinoma, both clear cell and non‑clear cell subtypes
• Glioblastoma and high‑grade astrocytoma

With 58 investigators, the center integrates translational research to bring laboratory discoveries to the bedside.

Studies explore symptom management and quality‑of‑life outcomes, such as the impact of depression on cancer prognosis and strategies to mitigate treatment‑related toxicities.

• Cancer‑related depressive disorders
• Management of chemotherapy‑induced neuropathy
• Patient‑reported outcome measures for symptom burden
• Biomarker‑driven diagnostics for early disease detection

The multidisciplinary team includes psycho‑oncology specialists to address the holistic needs of patients.

A focused trial evaluates the rapid antidepressant effect of psilocybin compared with ketamine in individuals experiencing depression alongside cancer treatment.

• Psilocybin versus ketamine for cancer‑associated depression
• Psychological support interventions during active therapy
• Anxiety reduction programs for oncology patients
• Long‑term mental health follow‑up after remission

By integrating mental health expertise, the site seeks to improve both emotional well‑being and clinical outcomes.

A diverse set of studies spans rare and hard‑to‑treat cancers, evaluating novel agents where standard therapy is lacking, and ensuring access to cutting‑edge treatments for patients with unmet needs.

• Rare sarcomas such as dedifferentiated liposarcoma
• High‑risk early‑stage breast cancer in adjuvant settings
• Immune‑checkpoint combinations in tumors without approved options
• Adaptive platform trials for multiple solid tumour histologies

The clinic’s flexible infrastructure supports rapid initiation of innovative protocols across therapeutic domains.